



Since ancient times, one of the most common physical complaints of 
mankind are headaches [1]. Having various forms, headaches affect 
a large part of the population and lower the quality of life by causing 
discomfort, limits in professional life, and problems in daily relations [2, 3]. 
The International Headache Society (IHS) determined the diagnosis 
criteria by splitting headaches into two groups, namely, primary and 
secondary headaches. More than 90% of headaches are primary, 
and most of those consist of migraines and tension-type headaches 
(TTHs) [4, 5]. Although observed commonly, their pathophysiology is 
still not known completely [6].
Mean platelet volume (MPV) is a laboratory marker used commonly for 
measuring platelet (Plt) activation [7]. Large Plts have a more active 
and thrombogenic potential, compared to small ones, metabolically 
and enzymatically [8]. Some defects in the Plt functions of migraine 
patients have been studied. In studies, Plt activation and aggregation 
in migraine patients due to secondary changes that possibly arose 
during attacks are suggested to be associated with migraine. Moreover, 
it has been emphasized that Plt clots may induce cortical spreading 
depression with ischemia and inflammation as a result of blockage 
of small veins and may result in aura-like symptoms and pulsating 
headache [9, 10]. TTH is a disease that is most commonly confused 
with migraines since its diagnosis is difficult, and it has a prevalence 
varying between 5.1% and 78% [11]. Myofascial mechanisms occupy
a significant space in the pathophysiology of TTH [12].
Migraine and TTH share common epidemiological and clinical 
characteristics in daily practice, and clinicians have trouble in the 
differentiation of these primary headache types [13]. Patients with 
episodic TTH generally have common migraine without aura. The 
diagnosis is important for primary headaches that cause a serious 
disability in society and have different treatments relative to each 
other. For this reason, accurate diagnosis and treatment are required 
for recurring headaches that negatively affect people and their 
families.
The purpose of our large-scale study is to determine whether episodic 
migraine patients and episodic TTH patients can be differentiated 
using increased MPV and MPV/Plt ratio, an indicator of Plt activation.
Materials and methods
The study was performed in accordance with the Declaration of 
Helsinki. Eighty patients with migraine-type headache, 80 patients 
with episodic TTH (who had applied to the Neurology Clinic of our 
hospital and diagnosed according to IHS criteria), and a control group 
consisting of 80 healthy subjects in a similar age and education level 
as these patients were included in this study. The control group 
was chosen from among the people who had applied to the Family 
Practice Clinic and Blood Bank, did not have any systemic disease, 
and did not smoke or drink alcohol. The permission of the local ethics 
committee was obtained for the study. Age, gender, occupation, 
starting age for headaches, frequency of attacks, attack period, and 
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the medicines used were recorded for all patients. Aura or non-aura 
migraines were recorded for the migraine group.
Patients with a chronic disease (hypertension, diabetes, chronic liver/
kidney/pulmonary disease, severe anemia, hematologic disease, 
and so on), chronic migraine and chronic TTH patients, patients 
receiving prophylactic treatment, patients with ischemic risk factors, 
patients with an acute or chronic infectious condition, patients 
using antibiotics, patients with intracranial space-occupying lesions, 
patients with malignity, patients with a history of pregnancy, and 
patients who had received treatment in the past year for anemia or 
polycythemia were excluded from the study. None of the patients 
had a history of surgery in the past 6 months. Furthermore, patients 
who drank alcohol and smoked, received anticoagulant and anti- 
inflammatory treatment, used systemic corticosteroids, and had 
systemic inflammatory disease were excluded from the study.
The severity of pain was assessed with the visual analog scale 
(VAS). For using VAS, patients are asked to rate the severity of their 
headaches on a 10 cm scale varying from zero (no pain) to 10 (the 
worst pain imaginable).
Plt measurement
For the study, blood samples were taken from arm veins in tubes 
containing ethylenediamine tetraacetic acid (EDTA) and stored at 
room temperature. Samples were studied within 2 hours. The Plt 
number was observed using a Siemens automated blood counter.
Statistical method
Statistical analyses were performed with IBM SPSS for Windows, 
Version 22.0. Numeric variables are summarized as mean ± 
standard deviation. Categorical variables are shown as numbers and 
percentages. Differences between groups with regard to categorical 
changes were studied with the chi-square test. Normality of numeric 
variables was examined using the Kolmogorov-Smirnov test, and 
the homogeneity of the variances was examined with the Levene 
test. Differences between groups with regard to numeric variables 
were examined using a t-test in separate groups. More than two 
independent intergroup differences were examined with one-way 
analysis of variance for numeric variables. If differences were 
determined, two-way comparisons were performed with Tukey’s 
honest significant difference test. The relation between numeric 
variables is presented with Spearman’s correlation coefficient. The 
intercept for MPV, Plt, and MPV/Plt ratio differentiating migraine and 
TTH groups was determined using receiver operating characteristic 
(ROC) curve analysis. The sensitivity and selectivity values for the 
best intercept are presented. Area under the ROC curve was 
calculated. The level of significance was taken as P < 0.05.
Findings
Eighty migraine patients, 80 TTH patients, and 80 healthy subjects 
are enrolled in the study. The average age of the migraine patients 
was 33.0 ± 7.9, and 57 were female (71.3%), while 23 were male 
(28.7%). There was no statistical difference with regard to age and 
gender between patients and healthy control groups (P < 0.05).
The average headache period for migraine patients was 4.4 ± 2.9 
year, and the average starting age for headaches was 28.7 ± 6.4 
years. Moreover, the average headache period for TTH patients was 
5.3 ± 3.1 year. They experienced 6.1 ± 2.6 days of headache monthly 
on average, and this pain lasted for 20.6 ± 8.5 hours on average. The 
average VAS score for the migraine patients was 7.9 ± 0.9, and it was 
higher than that in TTH by a statistically significant level (P < 0.05). 
The MPV was 10.84 ± 0.66 in migraine patients, 10.16 ± 0.59 in 
the TTH group, and 9.99 ± 0.69 in the healthy control group. When 
MPV, Plt number, and MPV/Plt ratio were compared between patient 
and healthy control groups, the migraine group was determined 
to be statistically different (P < 0.05). There was no statistical 
difference between TTH and control groups (Tab. I). The MPV/
Plt ratio was 0.046 ± 0.008 in migraine patients, 0.037 ± 0.009 in 
patients with TTH, and 0.036 ± 0.009 in the healthy control group 
(Fig. 1). The cutoff value of MPV/Plt ratio for differentiating migraine 
and TTH was 0.037. The sensitivity of this value was 92.5%, while 
specificity was 55% (Tab. II).
While 65 of the migraine patients (81.25%) had migraine without 
aura, 15 (18.75%) patients had migraine with aura. When MPV and 
MPV/Plt ratio were compared among patients who suffered from 
migraine with or without aura, there was no statistically significant 
difference (P > 0.05). MPV and Plt number were correlated with the 
headache period, starting age for headache, headache frequency, 
and severity of pain in the migraine patient group, and there was no
statistically significant correlation (Tab. III).
Table I. Mean platelet volume (MPV), platelet (Plt) number, and MPV/Plt ratio in migraine, tension-type headache (TTH), and healthy 
control groups
Migraine (n = 80) TTH (n = 80) Healthy control (n = 80) P
MPV 1084 ± 066 1016 ± 059 999 ± 069 < 0.001*
Plt number 2457 ± 513 2885 ± 671 2864 ± 534 < 0.001*
MPV/Plt ratio 0046 ± 0008 0037 ± 0009 0036 ± 0009 < 0.001*
Table II. Values differentiating migraine and tension-type headache groups
Cutoff Sensitivity Specificity AUC P
MPV >10.6 0.60 0.80 0.773 < 0.001*
Platelet (Plt) number < 237 0.65 0.75 0.718 < 0.001*




In this study, MPV and MPV/Plt ratio in migraine patients were 
compared with the MPV in TTH patients and normal population. 
According to the results obtained from the study, MPV in migraine 
patients was higher compared to the TTH patients and normal 
population, and this difference was statistically significant. The 
MPV/Plt ratio cutoff value for differentiating migraine and TTH was 
determined to be 0.037, and the sensitivity was 92.5% and specificity 
was 55% for this value.
Primary headaches comprise a health problem that causes the loss 
of capacity and performance. For this reason, accurate diagnosis and 
administration of suitable treatment is important. Since the diagnosis 
of migraine and other primary headaches depends only on the 
medical history obtained from the patient, clinicians have a hard 
time and, sometimes, they may apply the wrong treatment. TTH is 
the most common headache around the world; however, different 
prevalence values were determined in different studies. The IHS has 
determined the diagnosis criteria for patients suffering from TTH. 
However, TTH is the most common headache type that is confused 
with migraine without aura despite those criteria [14, 15]. Different 
biomarkers are used to differentiate TTH and migraine [16]. We 
suggest that MPV, a method that has not been used before, can be 
used in the differential diagnosis in order to differentiate the most 
commonly observed primary headache types. In our study, MPV and 
MPV/Plt ratio were higher in a statistically significant manner in the 
migrainegroup compared to the TTH group.
The deterioration in Plt functions has been suggested in previous 
studies in migraine pathophysiology [7, 17]. MPV is a sign of Plt 
activation, which has an important role in the pathophysiology of the 
atherothrombotic process. There are numerous studies demonstrating 
the occurrence of increased MPV in migraine patients. Large Plts contain 
denser molecules than small Plts, and they have more Plt potential 
as they are enzymatic and metabolically more active. There are more 
prothrombotic components in large Plts, such as thromboxane A2, 
collagen, and adenosine diphosphate (ADP). While MPV increases, 
Plt number tends to decrease. The reason may be increases in the 
production of Plts with increased aggregability from the bone marrow 
or increased Plt consumption [18, 19]. Zeller et al. reported increased 
Plt activation and leukocyte–Plt aggregation, determined by measuring 
P-selectin expression in the Plts of patients suffering from migraine 
without aura during the attack-free period compared to healthy controls 
[19]. In another study, Varol et al. determined that MPV is elevated in 
a nonspecific manner in 193 migraine patients compared to healthy 
controls [20]. However, Paradalier et al. found in their study that MPV 
and Plt number in migraine patients are not different from those in 
healthy controls [18]. In our study, we have determined that MPV is 
elevated to a statistically significant level in the migraine group and that 
the Plt number is decreased. The aspect of our study that distinguishes 
it from other studies and increases its value is that MPV and Plt levels 
have not been investigated for the differential diagnosis of migraine 
and TTHs before.
Many years ago, it was hypothesized that migraine is a primary Plt 
dysfunction [21]. It was determined that levels of Plt-activating factor, 
which has an important role in many inflammatory and thrombotic 
processes and is the mediator in phospholipid structure, increase 
during attacks [19]. In a study performed by Hanington et al., it was 
determined that spontaneous Plt aggregation and Plt adhesion are 
Fig. 1. Average mean platelet volume (MPV)/platelet (Plt) ratios for migraine, tension-type headache, and healthy control groups
Table III. Correlations in the migraine patient group
Mean platelet volume (MPV) Platelet (Plt) number MPV/Plt ratio
Correlation coefficient P Correlation coefficient P Correlation coefficient P
Headache period, year 0.078 0.490 0.146 0.196 -0.076 0.501
Starting age for headache, year 0.032 0.781 -0.164 0.147 0.137 0.225
Days of headache in a month, day 0.403 < 0.001 -0.089 0.431 0.205 0.068
Visual analog scale score, n 0.215 0.056 -0.021 0.852 0.077 0.498
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higher in the Plts of migraine patients in the headache-free period 
compared to the same in the healthy control group, and therefore, 
they suggested that Plt behavior may have a role in recurring migraine 
attacks and in the start of attacks since it is different in migraine 
patients relative to that in healthy people [22]. We have determined 
in our study that MPV and MPV/Plt ratio increase in a statistically 
significant manner in migraine patients in the period between attacks. 
We have determined that this increase is independent of the starting 
age, period, and severity of the disease. Furthermore, this increase 
was of the same level in migraine patients with or without aura. 
We think that this also supports the hypothesis that there is a Plt 
dysfunction in the pathophysiology of migraine.
In the hypothesis suggested for the pathophysiology of TTH, it is 
indicated that there is pain modulation with nociceptive stimulations 
from pericranial myofascial tissues causing sensitization at the upper 
cervical spinal dorsal root trigeminal core level and secondarily the 
sensitization of the supraspinal structures such as the thalamus or 
somatosensorial cortex [23]. In the study of Bendtsen et al., performed 
on TTH patients, in vivo interstitial concentrations of inflammatory 
mediators and metabolites were determined to be normal [24]. In 
our study, we determined that MPV and MPV/Plt ratio have similar 
levels in the healthy population. We have used these ratios in the 
differential diagnosis of migraine-type headaches, which are often 
confused with one another.
The limitations of our study are that 1) MPV is a biomarker easily 
affected by the preanalytical process after sampling, 2) tubes 
containing EDTA in which the samples are stored may alter Plt 
type and increase MPV, 3) although the samples are studied within 
2 hours after sampling, MPV may change proportionally with time. 
Consequently, MPV is an important sign of Plt activation, which has 
an important role in the pathophysiology of the atherothrombotic 
process. Although MPV correlation has been examined in migraine 
patients before, its relation in the differentiation of TTH has never 
been studied. We have demonstrated that most commonly confused 
primary headache types may be differentiated by using MPV and 
MPV/Plt ratio, and therefore, the disability caused by migraine 
and unsuitable, unnecessary, and long-term drug therapies may be 
prevented for patients. Our results support our diagnosis.
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